Patent: 8,889,834

Summary for Patent: 8,889,834

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/260,985
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,889,834
Patent Claims:	see list of patent claims
Scope and claims summary:	T-Cell Receptor Modulation for Cancer Immunotherapy: An In-Depth Analysis of United States Patent 8889834 United States Patent 8889834, awarded to Merck Sharp & Dohme Corp. (Operating as MSD outside the United States and Canada), pertains to T-cell receptor modulation for cancer immunotherapy. The patent's claims and scope have significant implications for the development of innovative cancer treatments. Background Cancer immunotherapy has gained significant attention in recent years due to its potential to induce long-term, targeted responses against malignant cells. T-cell receptors (TCRs) play a crucial role in recognizing and eliminating cancer cells. By modulating TCR signaling, researchers aim to enhance the efficacy of cancer immunotherapies. Patent Claims and Scope The patent claims focus on compositions, methods, and apparatus for modulating TCR signaling to enhance cancer immunotherapies. Specifically, the claims cover: Modulating ligand binding to TCRs: The patent claims novel compositions and methods for modulating ligand binding to TCRs to enhance cancer immunotherapy. Immobilized ligands: The claims cover the use of immobilized ligands to modulate TCR signaling, which can improve the affinity and specificity of TCR-ligand interactions. TKR-M-like constructs: The patent claims modifications to TCR-M-like constructs, such as incorporating linker sequences, to improve TCR signaling. T-tetramers: The patent's claims cover novel tetramer-based compositions for TCR engagement and modulation. Relevance to Cancer Immunotherapy The claims and scope of United States Patent 8889834 have significant implications for the development of innovative cancer immunotherapies. By modulating TCR signaling, researchers can enhance the efficacy of cancer vaccines, adoptive T-cell therapies, and other forms of immunotherapy. The patent's emphasis on TCR modulation, ligand binding, and immobilization highlights the importance of TCR interactions in cancer immunotherapy. By optimizing TCR signaling, researchers can: Improve T-cell activation and expansion Enhance T-cell persistence and homing Increase cytolytic activity against tumor cells Implications and Future Directions United States Patent 8889834 provides a foundation for the development of innovative cancer immunotherapies. Researchers and industry stakeholders can leverage the patent's claims and scope to design novel compositions and methods for modulating TCR signaling. Future directions for cancer immunotherapy may include: Investigation of novel TCR ligands and binding modes Development of immobilized ligand-based compositions Optimization of TCR-M-like constructs and T-tetramers Combination therapies that target multiple signaling pathways The landscape of cancer immunotherapy continues to evolve, with a focus on modulating TCR signaling to enhance treatment outcomes. United States Patent 8889834 provides a critical foundation for further research and development in this field.

Details for Patent 8,889,834

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	8,889,834	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	8,889,834	2027-08-23

International Patent Family for US Patent 8,889,834

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558
United States of America	9920134
United States of America	9493576
United States of America	9056915
United States of America	9045547
United States of America	8981064
United States of America	8883983